Inhibition of the BMP pathway suppresses tumor growth via downregulation of EGFR in MEK/ERK-dependent colorectal cancer
暂无分享,去创建一个
K. Obama | R. Coffey | Y. Tamada | M. Kamada | Yoshihisa Tanaka | M. Nakazawa | Shota Shimizu | K. Kawada | J. Kondo | K. Onuma | Yohei Harada | Y. Fujiwara | Yasushi Okuno | Masahiro Inoue | Kasumi Ota
[1] K. Miyazono,et al. Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years , 2022, Frontiers in Cell and Developmental Biology.
[2] D. Threadgill,et al. Cross‐talk between EGFR and BMP signals regulates chondrocyte maturation during endochondral ossification , 2021, Developmental dynamics : an official publication of the American Association of Anatomists.
[3] L. Siu,et al. Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. , 2021, Clinical colorectal cancer.
[4] L. V. Valkenburg-van Iersel,et al. Combined targeted therapy for BRAF mutant metastatic colorectal cancer: are we there yet? , 2021, Digestive Medicine Research.
[5] S. Angaji,et al. LRIG1 expression and colorectal cancer prognosis , 2020, BMC Medical Genomics.
[6] W. Jiang,et al. Noggin is associated with a poor prognosis of gastric cancer by promoting the proliferation of gastric cancer cells via the upregulation of EGFR. , 2020, International Journal of Oncology.
[7] Y. Cho,et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer , 2020, Nature Genetics.
[8] Z. Wainberg,et al. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors , 2019, Front. Oncol..
[9] M. Inoue,et al. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy , 2019, Cells.
[10] Yan-ting Zhu,et al. Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis , 2018, Journal of Cancer.
[11] J. Neefjes,et al. The EGFR odyssey – from activation to destruction in space and time , 2017, Journal of Cell Science.
[12] M. Ohue,et al. In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer , 2017, PloS one.
[13] Bing Zhao,et al. BMP restricts stemness of intestinal Lgr5+ stem cells by directly suppressing their signature genes , 2017, Nature Communications.
[14] Jingwen Ye,et al. Lrig1 is a positive prognostic marker in hepatocellular carcinoma , 2016, OncoTargets and therapy.
[15] C. Hong,et al. Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. , 2016, Biochemical Society transactions.
[16] Zibo Zhao,et al. Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer , 2015, Medicine.
[17] K. Edlund,et al. LRIG1 is a prognostic biomarker in non-small cell lung cancer , 2015, Acta oncologica.
[18] R. Coffey,et al. LRIG1 Regulates Ontogeny of Smooth Muscle-Derived Subsets of Interstitial Cells of Cajal in Mice. , 2015, Gastroenterology.
[19] G. R. van den Brink,et al. A protocol for lentiviral transduction and downstream analysis of intestinal organoids. , 2015, Journal of visualized experiments : JoVE.
[20] R. Tollenaar,et al. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC , 2014, British Journal of Cancer.
[21] B. Barres,et al. BMP Signaling in Astrocytes Downregulates EGFR to Modulate Survival and Maturation , 2014, PloS one.
[22] C. Futter,et al. EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.
[23] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[24] R. Coffey,et al. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor , 2013, British Journal of Cancer.
[25] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[26] P. Ordóñez-Morán,et al. Lrig1: a new master regulator of epithelial stem cells , 2012, The EMBO journal.
[27] Bruce J. Aronow,et al. The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor Suppressor , 2012, Cell.
[28] O. Griffith,et al. Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer , 2011, Molecular Cancer Research.
[29] H. Iishi,et al. Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer , 2011, Proceedings of the National Academy of Sciences.
[30] D. Jonker,et al. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. , 2011, Discovery medicine.
[31] L. Ricci-Vitiani,et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. , 2011, Gastroenterology.
[32] A. Ruiz i Altaba,et al. BMP signaling promotes the growth of primary human colon carcinomas in vivo. , 2010, Journal of molecular cell biology.
[33] E. Maspero,et al. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation , 2010, The Journal of cell biology.
[34] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[35] Angelique M. Nelson,et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. , 2007, Blood.
[36] Suet Yi Leung,et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors , 2007, Proceedings of the National Academy of Sciences.
[37] J. Carethers,et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. , 2006, American journal of physiology. Gastrointestinal and liver physiology.
[38] Xiuli Wu,et al. The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases* , 2004, Journal of Biological Chemistry.
[39] Ossama Tawfik,et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt–β-catenin signaling , 2004, Nature Genetics.
[40] I. Amit,et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation , 2004, The EMBO journal.